zintick
ANVS Annovis BioCorporate actionBankruptcy, delistings and restatements

Annovis Bio Receives NYSE Notice on Continued Listing Standard Shortfall

The notice cites a 30-day average market capitalization of about $48.4 million and a stockholders' deficit of about $(4.3) million.

By Zintick Team · Editor: Kratik Mehta
Published

Researchers at breakthrough after evaluation on the computer in the laboratory looking for Covid-19 vaccine
Photo: True Touch Lifestyle/Shutterstock.com

Key terms

  • NYSE notice received Oct. 29 under Section 802.01B for market cap and equity shortfalls
  • 30-day average market cap about $48.4 million; stockholders' deficit about $(4.3) million
  • Compliance plan due within 45 days; 9-month cure period from receipt of the notice
  • Stock continues trading as ANVS with a .BC designation during the cure period

Annovis Bio, Inc. (NYSE: ANVS) said it received a notice from the New York Stock Exchange that it is no longer in compliance with NYSE continued listing standards, the company disclosed in an 8-K filed Friday, Oct. 30.

The notice, received Oct. 29, cites Section 802.01B of the NYSE Listed Company Manual. The exchange's test requires an average market capitalization over a consecutive 30 trading-day period of at least $50 million, alongside stockholders' equity of at least $50 million. Annovis fell short on both measures at the same time.

As of Oct. 28, the company's 30 trading-day average market capitalization was about $48.4 million. Its last reported stockholders' deficit, as of June 30, 2026, was about $(4.3) million.

Compliance plan and deadline

Annovis has told the NYSE it will submit a plan within 45 days of the notice describing definitive action to bring it back into conformity with Section 802.01B within 9 months of receiving the notice. The NYSE will then have 45 days to decide whether the company has reasonably demonstrated it can meet the standard within that period.

If the plan is not submitted on time or is not accepted, the NYSE will initiate delisting proceedings. If the plan is accepted, the stock stays listed and trades on the NYSE during the cure period, subject to compliance with the plan. The NYSE will review progress semi-annually. If the company does not comply with the plan or meet the standards at the end of the 9-month period, suspension and delisting procedures will begin promptly.

Trading continues for now

The notice has no immediate effect on the listing. Common stock will keep trading under the symbol "ANVS," but with a ".BC" designation indicating it is below the NYSE continued listing criteria. The indicator will be removed once the company regains compliance. The NYSE may also act quickly if the shares trade at abnormally low levels, which it generally views as below $0.10.

The company said the notice does not affect its business operations or its SEC reporting obligations, and does not cause a default under its material debt or other agreements.

Sources

Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.

ANVS page →

Filings, figures and price history are on the Annovis Bio page.